Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 10, 2026Lara D. Veeken

SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2-3 trials

View Full Paper
Ask AI
Bookmark
Share

Authors

DJDiogo JesusUniversity of Beira InteriorCHCarla HenriquesPolytechnic Institute of ViseuAMAna MatosDigital Equipment (Germany)

Discussion

Loading...

Member takes

Implication

Efficacy measures in SLE trials show significant improvements in outcomes, indicating strong utility for clinical assessments.

Key Points

  • This research aims to evaluate the SLE-DAS responder index as a reliable outcome measure in SLE trials.
  • Assessment of the SLE-DAS RI in phase 2-3 trials of anifrolumab.
  • Comparison of SLE-DAS RI with other efficacy endpoints.
  • Evaluation of improvements in patient-reported outcomes.
  • SLE-DAS RI demonstrates robust performance as an efficacy endpoint.
  • Associated with sustained disease control over time.
  • Facilitates accurate identification of meaningful outcomes in trial design.

Cite This Study

Jesus et al. (2026) studied this question.

synapsesocial.com/papers/69d8958f6c1944d70ce068dchttps://doi.org/10.1093/rheumatology/keag177
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus2011 · 1,697 citations
  2. 2SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies2025 · 3 citations
  3. 3Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally2021 · 10 citations
  4. 4Qualitative validation of the FACIT-Fatigue scale in systemic lupus erythematosus2013 · 82 citations
  5. 5The MOS 36-ltem Short-Form Health Survey (SF-36)1992 · 30,291 citations